迈威生物发行境外上市外资股（H股）获得中国证监会备案

Core Viewpoint - The company, Maiwei Biotechnology, has received approval from the China Securities Regulatory Commission for its overseas listing plan, indicating a significant step towards expanding its capital base and market presence [1] Group 1: Company Announcement - Maiwei Biotechnology announced that it plans to issue up to 62.6646 million overseas listed ordinary shares [1] - The company intends to list these shares on the Hong Kong Stock Exchange [1]